• Five patients achieved complete response, an unprecedented 7.8% rate
• Median overall survival improved by 2 months compared to chemotherapy alone
• No additional toxicity burden observed

Amplia Therapeutics Limited has announced mature data from the ongoing ACCENT clinical trial in advanced pancreatic cancer, in which its lead drug narmafotinib is combined with chemotherapy. The data show a median overall survival of 11.1 months, and five complete responses recorded to date. Expert central reading of the clinical data has reclassified some of the response data, identifying an additional four confirmed complete responses (CRs), bringing the total CR's for all patients in the ACCENT trial receiving a 400 mg dose of narmafotinib to five, resulting in a CR rate of 7.8% (5/64) which is unprecedented in this indication. An additional confirmed partial response (PR) has also been identified, resulting in an updated Objective Response Rate (ORR) of 35.9% (23/64) for all patients in both stages of the 1b/2a ACCENT trial on a 400 mg dose of narmafotinib. The median Overall Survival (mOS) of 11.1 months is an approximate two-month improvement when compared to clinical studies of the gemcitabine-Abraxane® chemotherapy alone, including the MPACT study. Narmafotinib continues to be well tolerated by patients with the adverse effect profile of the narmafotinib-chemotherapy combination similar to chemotherapy alone.

The ACCENT trial has achieved a median Overall Survival (mOS) of 11.1 months, which is a 2-month improvement compared to chemotherapy alone.

The Company has been selected to present its ACCENT trial data, along with additional data derived from further analysis, at the annual meeting of the American Association of Cancer Research (AACR) in April 2026.